CLAIMS

1. Use of reboxetine in the manufacture of a medicament for the treatment of narcolepsy with cataplexy in a human being, wherein reboxetine is to be administered at least once daily for at least three weeks, wherein the human being has a cataplexy subscore of at least 10 prior to receiving reboxetine, and wherein, two weeks from the beginning of treatment, the human being experiences a reduction in the number of cataplexy attacks in a week, a reduction in the Epworth Sleepiness Scale score, a decrease in the cataplexy subscore on the Ullanlinna Narcolepsy Scale (NUS), or a reduction in the Maintenance of Wakefulness Test score as a result of the treatment.

2. A kit comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being, wherein reboxetine is to be administered at least once daily for at least three weeks, and wherein the human being has a cataplexy subscore of at least 10 prior to receiving reboxetine.

3. The use of claim 1, or the kit of claim 2, wherein reboxetine is to be administered twice daily, wherein a first dosage form is to be administered in the morning and a second dosage form is to be administered ~~about~~ 2 hours to ~~about~~ 6 hours later.

4. The use of claim 1, or the kit of claim 2, wherein the reboxetine is in a dosage form that is to be administered daily, wherein the dosage form contains a first release component comprising reboxetine and a second release component comprising reboxetine, wherein the first release component provides a first local maximum in the plasma concentration of reboxetine and the second release component provides a second local maximum in the plasma concentration of reboxetine, wherein the first local maximum in the plasma concentration of reboxetine occurs ~~about~~ 2 to ~~about~~ 6 hours before the second local maximum in the plasma concentration of reboxetine.

5. The use, or the kit of claim 4, wherein the second local maximum in the plasma concentration of reboxetine occurs ~~about~~ 4 to ~~about~~ 6 hours after the first local maximum in the plasma concentration of reboxetine.

6. The use of claim 1, or the kit of claim 2, wherein the human being is selected for not suffering from depression.

7. The use of claim 1, or the kit of claim 2, wherein the dose amount of reboxetine is increased for 1 to 7 days, and then maintained constant at a total daily dose of ~~about~~ 0.006 mmol to ~~about~~ 0.08 mmol.

8. The use of claim 1, or the kit of claim 2, wherein the reboxetine is in a dosage form and the dosage form contains ~~about~~ 5 mg of reboxetine.

9. The use of claim 1, or the kit of claim 2, wherein the reboxetine is in a dosage form and the dosage form contains ~~about~~ 10 mg of reboxetine.

10. The use, or the kit of claim 8, wherein the dosage form is to be administered once daily or twice daily for at least three weeks.

11. The use, or the kit of claim 9, wherein the dosage form is to be administered once daily or twice daily for at least three weeks.

12. The use of claim 1, or the kit of claim 2, wherein the human being experiences an increase in sleep latency on the multiple sleep latency test (MSLT).

13. The use, or the kit of claim 12, wherein the human being experiences an increase of at least 10% in sleep latency on the MSLT.

14. The use, or the kit of claim 12, wherein the human being experiences an increase of at least 20% in sleep latency on the MSLT.

15. The use, or the kit of claim 12, wherein the human being experiences an increase of ~~about~~ 30% to ~~about~~ 60% in sleep latency on the MSLT.

16. The use of claim 1, or the kit of claim 2, wherein the human being experiences a decrease of at least 15% in the cataplexy subscore on the UNS.

17. The use, or the kit of claim 16, wherein the human being experiences a decrease of at least 30% in the cataplexy subscore on the UNS.

18. The use, or the kit of claim 16, wherein the human being experiences a decrease of ~~about~~ 20% to ~~about~~ 70% in the cataplexy subscore on the UNS.

19. The use, or the kit of claim 16, wherein the human being has a cataplexy subscore of ~~about~~ 0 after administration of reboxetine.